6. Literaturverzeichnis

1 Klahr S, Schreiner G, Ichikawa I : The progression of renal disease. N Engl J Med. 1988, 318, S.1657-1666,

2 Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994, 331, S.1286-1292,

3 Reyes AA, Purkerson ML, Karl I, Klahr S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kid Dis. 1992, 20, S.168-176,

4 Katoh T, Takahashi K, Klahr S, Reyes AA, Badr KF: L-arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int. 1994, 45, S.1346-1354,

5 Reyes AA, Karl IE, Kissane J, Klahr S: L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats. J Am Soc Nephrol. 1993, 4, S.1039-1045,

6 Andrade L, Campos SB, Seguro AC: Hypercholesterolemia aggravates radiocontrast nephrotxicity: protective role of L-arginine. Kidney Int. 1998, 53 (6), S.1736-1742,

7 Reckelhoff JF, Kellum JA, Jr., Racusen LC, Hildebrandt DA: Long-term dietary supplementation with L-arginine prevents age-related reduction in renal function. Am J Physiol. 1997, 272, S.R1768-1774,

8 Bohle A: Die Bedeutung des Niereninterstitiums für die Nierenfunktion. Klin Wochenschr. 1982, 60, S.1186-1190,

9 Peters H, Border WA, Noble NA: Angiotensin I und L-arginine in tissue fibrosis: more than blood pressure. Kid Int. 1997, 51, S.1481-1486,

10 Peters H, Border WA, Noble NA: From rats to men: A perspective on dietary L-arginine supplementation in human renal disease. Nephrol Dial Transplant. 1999, 14, S.1640-1660,

11 Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group11. N Eng J Med. 1994, 330, S.877-884,

12 Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study. N Engl J Med. 1993, 329, S.1456-1462,

13 Okuda S, Nakamura T,Yamamoto T, Rouslahti E, Border WA: Dietary protein restriction rapidly reduces transforming growth factor beta 1 expression in experimental glomerulonephritis. Procl Natl Acad Sci USA . 1991, 88, S.9765-9769,

14 Ohta K, Kim S, Hamaguchi A, Yukimura T, Miura K, Takaori K, Iwao H: Role of angiotensin II in extracellular matrix and transforming growth factor beta 1 expression in hypertensive rats. Eur J Pharmacol . 1994, 269, S.115-119,

15 Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature. 1992, 360, S.361-364,

16 Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppresion of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990, 346, S.371-374,

17 Border WA, Ruoslathi E: Transforming growth factor beta in disease: the dark side of tisue repair. J Clin Invest. 1992, 90, S.01. Jul,

18 Noble NA, Border WA: Angiotensin II in renal fibrosis: Should TGF-beta rather than blood pressure be the therapeutic target?. Semin Nephrol. 1997, 17, S.455-466,

19 Reyes AA, Karl I, Klahr S: Role of arginine in health and in renal disease. Am J Physiol. 1994, 267, S.F331-F346,

20 Barbul A: Arginine: biochemistry, physiology an therapeutic implications. J Parenter Enteral Nutr. 1986, 10, S.227-238,

21 Furchgott RF, Zawadzki JV: the obligatory role of endothelial cells in the relaxation of arterial smooth muscle cells by acetylcholin. Nature. 1980, 288, S.373-376,

22 Ignarro LJ, Buga GM, Wood KS, Byrne RE, Chaudhuri G: Endothelium-derived relaxing factor produced from artery and vein is nitric oxide. Proc Nat acad Sci. 1987, 84, S.9265-9269,

23 Palmer RMJ, Ferrige AJ, Moncada S: Nitric oxide releases accounts for the biological activity of endothelium derived relaxing factor. Nature. 1987, 327, S.524-526,

24 Castillo L, Sanchez M, Vogt J, Chapman TE, DeRojas Walker TC, Tannenbaum SR, Ajami AM, young VR: Plasma arginine, citrulline and ornithine kinetics in adults with observation on nitric oxide synthesis. Am J Physiol. 1995, 268, S.E360-E367,

25 Kone BS, Baylis C: Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am J Physiol. 1997, 272, S.F561-F578,

26 Moncada S: Nitric oxide in the vasculature: physiology and pathophysiology. Ann NY Acad Sci. 1997, 811, S.60-67,

27 Bachmann S, Mudel P: Nitric oxide in the kidney: synthesis, localization and function. Am J Kid Dis. 1994, 24, S.112-129,

28 Beckmann JS, Koppenol WH: Nitric oxide, superoxide and peroxynitrite: the good, the bad and the ugly. Am J Physiol. 1996, 271, S.C1424-C1437,

29 Sandau K, Pfeilschifter J, Brune B: Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis. Kid Int. 1997, 52, S.378-386,

30 Knowle RG, Moncada S: Nitric oxide synthases in mammals. Biochem J . 1994, 298, S.249-258,

31 Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994, 269, S.13725-13728,

32 Hibbs JB Jr, Taintor RR, Vavrin Z: Macrophage cytotoxicity: role for deaminase and iminonitrogen oxidation to nitrate. Science. 1987, 235, S.473-476,

33 Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM: Nitric oxide a cytotoxic activated macrophageeffector molecule. Biochem Biophys Res Comm. 1988, 157, S.87-94,

34 Pfeilschifter J, Eberhardt W, Hummel R, Kunz D, Muhl H, Nitsch D, Pluss C, Walker G: Therapeutic strategies für the inhibition of inducible nitric oxide-synthase - Potential for a novel class of anti-inflammatory agents. Cell Biol Int. 1996, 20, S.51-58,

35 Peters H, Border WA, Noble NA: L-arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. Kid Int. 1999, 55, S.2264-273,

36 Peters H, Noble NA: dietary L-arginine in renal disease. Sem Nephrol. 1996, 16 No. 6, S.567-575,

37 Noris M, Remuzzi G: Physiology and Pathophysiology of nitric oxide in chronic renal disease. Proc Assoc Am Physicians. 1999, 111, S.602-610,

38 Kone BC: Nitric oxide in renal health and disease. Am J Kid Dis. 1997, 30, S.311-333,

41 Forstermann U, Closs EI, Pollock JS, nakane M, Schwar P, Gath I, Kleinert H: Nitric oxide synthase isozymes. Characterization, purification, molecular cloning and functions. Hypertension. 1994, 23, S.1121-1131,

43 Trachtmann H, Futterweit S, Singhal P: Nitric oxide modulates the synthesis of extracellulär matrix proteins in cultured rat mesangial cells. Biochem Biophys Res Commun. 1995, 207, S.120-125,

44 Trachtmann H, Futterweit S, Garg P, Reddy K, Singhal P: Nitric oxide stimulates the activity of a 72-kDa neutral matrix metalloproteinase in cultured rat mesangial cells. Biochem Biophys Res Commun. 1996, 218, S.704-708,

45 Craven PA, Studer RK, Felder J, Phillips S, DeRubertis FR: Nitric oxide inhibition of transfoorming grwoth factor-beta and collagen sythesis in mesangial cells. Diabetes. 1997, 46, S.671-681,

46 Shultz PJ, Schorer AE, Raij L: Effects of endothelium-derived relaxing factor and nitric oxide on rat mesangial cells. Am J Physiol. 1990, 258, S.F162-F167,

47 Hogan M, Cerami A, Bucala R: Advanced glycolisation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus. J Clin Invest. 1992, 90, S.1110-1115,

50 Bagchus WM, Hoedemaker PJ, Rozing J, Bakker WW: Glomerulonephritis induced by monoclonal Anti-thy-1.1antibodies. Lab Invest. 1986, 55, S.680-687,

51 Narita I, Border WA, Ketteler M, Noble NA: Nitric oxide mediates immunologic injury to kidney mesangium in experimental glomerulonephritis. Lab Invest. 1995, 72, S.17-24,

52 Schlondorff D, Nelson PJ, Luckow B, Banas B: Chemokines and renal disease. Kidney Int. 1997, 51, S.610-621,

53 Floege J, Grone HJ: Progression of renal failure: What is the role of Zytokines. Nephrol Dial Transplant. 1995, 10, S.1575-1586,

54 Peters H, Border WA, Noble NA: Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis. Kidney Int. 2000, 57, S.922-1001,

55 Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP: Plasminogen activator inhibitor type 1 is a potential target in renal fibrosis. Kidney Int. 2000, 58, S.1841-1850,

56 Tierschutzgesetz vom 02.09.1975. Band BGBI. 2002 S.2313-2610 Ref. Type: Patent,

57 Tierschutzgesetz in der Fassung vom 17.02.1993. Band BGB1. 1993 S.254 zuletzt geändert durch Artikel 86 des EWR-Ausführungsgesetzes vom 27.04.1993 BGB II S. 512 Ref. Type: Patent,

58 Feelisch M : The use of nitric oxide donors in pharmacological studies. Nauyn Schmiedebergs Arch Pharmacol. 1998, 358, S.113-122 ,

59 Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest. 1992, 90, S.278-281,

61 van den Meiracker A, van der Linde N, Broere A, Derkx F, Boomsma F: Effects of L-Arginine and L-NAME on the renal function in hypertensive and normotensive subjects. Nephron. 2002, 91, S.444-451,

62 Benigni A, Zoija C, Norris M et al: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis. 1999, 33, S.746-753,

63 Rangan GK, Wang Y, Harris DC: Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol. 2001, 12, S.1696-1705,

64 Attia DM, Ni ZN, Boer P et al.: Proteinuria is preceeded by decreased nitric oxide synthesis and prevented by a NO donor in cholesterol-fed rats. Kidney Int. 2002, 61, S.1776-1787,

65 Peters H, Noble NA, Border WA: Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int. 1998, 54, S.1575-1583,

66 Vodovotz Y, Kwon NS, Pospischil M, Manning J, Paik J, Nathan C: Inactivation of nitric oxide synthase after prolonged incubation of mouse macrophages with IFN-gamma and bacterial lipopolysaccharide, J Immunol. 1994, 152 (8), S. 4110-8,

67 Stuehr DJ, Cho HJ, Kwon NS, Weise MF, Nathan CF: Purification and characterization of the cytokine-induced macrophage nitric oxide synthase: an FAD- and FMN-containing flavoprotein. Proc Natl Acad Sci U S A. 1991, 88 (17), S. 7773-7777,

68 Rennard SI, Berg R, Martin GR, Foidart JM, Robey PG: Enzyme-linked immunoassay (ELISA) for connective tissue components. Anla Biochem. 1980, 104, S.205-214,

69 Schmidt RJ, Baylis C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int. 2000, 58, S.1261-1266,

70 Reyes AA, Karl IE, Yates J, Klahr S: Low plasma and renal tissue levels in rats with obstructive nephropathy. Kidney Int. 1994, 45, S.782-787,

71 Baylis C, Vallance P: Measurement of nitrite and nitrate levels in plasma and urine - What does this measure tell us about the activity of the enogenous nitric oxide system?. Curr Opin Nephrol Hypertens. 1998, 7, S.59-62,

72 Chen PY, Sanders PW: L-arginine abrogates salt-sensitive hypertension in Dahl/Rapp rats. J Clin Invest. 1991, 88, S.1559-1567,

73 Shihab FS, Yi H, Bennet WM, Andoh TF: Effect of nitric oxide modulation on TGF-beta1 and matrix proteins in chronic cyclosporine nephrotoxicity. Kidney Int. 2000, 58, S.1174-1185,

74 Ribeiro MO, Antunes E, Muscara MN et al.: Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertens. 1995, 26, S.150-155,

75 Wenzel UO, Wolf F, Thaiss F et. al: Renovascular hypertension does not influence repair of glomerular lesions induced by anti-thymocyte glomerulonephritis. Kidney Int. 2000, 58, S.1135-1147,

76 Vandenbossche GM, De Muyunck C, Colardyn F, Remon JP: Light stability of molsidominein infusion fluids. J Pharm Pharmacol. 1993, 45, S.486-488,

77 Mattson DL, Wu F: Nitric oxide synthase activity and isoforms in rat renal vasculatur. Hypertens. 2000, 35, S.337-341,

78 Öztürk H, Aldemir M, Büyükbayram H et al.: The effects of the nitric oxide donor molsidomine prevent warm ischemia-reperfusion injury in the rat renal-A functional and histopathological study. Int Urol Nephrol. 2001, 32, S.601-607,

79 Rangan GK, Wang Y, Harris DC: Pharmacological modulators of nitric oxide exacerbate tubuloinstertial inflammation in proteinuric rats. J Am Soc Nephrol. 2001, 12, S.1696-1705,

80 Nori E, Peresleni T, Miller F, Goligorsky MS: In vivo targeting of inducible NO synthase with oligodesoxynucleotides protects rat kidney against ischemia. J Clin Invest. 1996, 97, S.1377-2383,

81 Vos IH, Joles JA, Schurink M, et al.: Inhibition of inducible nitric oxide synthase improves graft function and reduces tubulointerstitial injury in renal allograft rejection. Eur J Pharmacol. 2000, 391, S.31-38,

82 Noiri E, Peresleni T, Miller F, Goligorsky MS: The role of nitric oxide in the pathogenesis of spontaneus murine autoimmune disease: Increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-Monomethyl-L-Arginine. J Clin Invest. 1996, 97, S.2377-2383,

83 Kashem A, Endoh M, Yano N, et al.: Expression of inducible-NOS in human glomerulonephritis. The possible source is infiltrating monocytes/macrophages. Kidney Int. 1996, 50, S.392-399,

84 Peters H, Border WA, Rückert M et al.: L-Arginine supplementation accelerates renal fibrosis and shortens life span in experimental lupus nephritis. Kidney Int. 2003, 63, S.1382-1392,

85 Nozik ES, Huang YC, Piantadosi CA: L-Arginine enhances injury in the isolated rappit lung during hypoxia. Respir Physiol. 1995, 100, S.63-74,

86 Neilly PJ, Kirk SJ, Gardiner KR et al.: Manipulation of the L-arginine-nitric oxide pathway in experimental colitis. BR J Surg. 1995, 82, S.1188-1191,

87 Zhang F, Casey RM, Ross ME, Iadecola S: Aminoguanidine ameliorates and L-arginine worsens brain damage from intraluminal middle cerebral artery occlusion. Stroke. 1996, 27, S.317-323,

88 Reyes AA, Porras BH, Chasalow FI, Klahr S: L-Arginine decreases the infiltration of the kidney by macrophages in obstructive nephropathy and puromycin-induced nephrosis. Kidney Int. 1994, 45, S.782-787,

89 Reyes AA, Klahr S: Dietary supplementation of L-arginine ameliorates renal hypertrophy in rats fed a high-protein diet. Proc Soc Exp Biol Med. 1994, 206, S.157-161,

90 Katoh T, Takahashi k, Klahr S, et al.: Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy. J Am Soc Nephrol. 1994, 4, S.1690-1694,

91 Wu G, Meininger CJ: Arginine nutrition and cardiovascular function. J Nutr. 2000, 130, S.2626-2629,

92 De Nicolal, Bellizzi V, Minutolo R, et al.: Randomized, double-blind, placebo-controlled study of arginine supplementation in chronic renal failure. Kidney Int. 1999, 56, S.674-684,

93 Eisenberger: Abstract. J Am Soc Nephrol. 1999, 10, S.727-728A,

94 Ketteler M, Ikegaya N, Brees DK, Border WA, Noble NA: L-arginine metabolism in immune-mediated glomerulonephritis in the rat. Am J Kidney Dis. 1996, 28, S.878-887,

95 Narita I, Border WA, Ketteler M, Ruoslahti E, Noble NA: L-arginine may mediate the therapeutic effects of low protein diets. Proc Natl Acad Sci USA. 1995, 92, S.4552-4556,

96 Yamamoto T, Noble NA, Miller DE, Border WA: Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int. 1994, 45, S.916-927,

97 Benigni A, Perico N, Remuzzi G: Enothelin antagonists and renal protection. J Cardiovasc Pharmacol. 2000, 35, S.75-78,

98 Sporn MB, Roberts AB: A major advance in the use of growth factors to enhance wound healing. J Clin Invest. 1993, 92, S.2565-2566,

99 Romberger DJ: Fibronectin. Int J Biochem Cell Biol. 1997, 29, S.939-943,

100 Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW: ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MM-2 cascade. Kidney Int. 1995, 47, S.664-671,

101 Eitzman DT, McCoy RC, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH: Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996, 97, S.232-237,

102 Yamamoto T, Mundy CA, Wilson CB: Quantitative and qualitative studies of antibody induced mesangial cell damage in the rat. Kidney Int. 1987, 32, S.514-525,

103 Eberhadt W, Beeg T, Beck KF et al.: Nitric oxide modulates expression of metalloproteinase-9 in rat mesangial cells. Kidney INt. 2000, 57, S.59-69,

104 Arnal FJ, Warin L, Miche JB: Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 1992, 90, S.647-652,

105 Frei U, Schober-Halstenberg HJ: Nierenersatztherapie in Deutschland. Band QuaSi-Niere Jahresbericht 2001/2002. Berlin ,

106 United States Renal Data Systems: Annual Data Report 2003. Minneapolis, USA,

107 Green LC, Wagner DA, Glogowki J et al.: Analysis of nitrate, nitrite and 15N-nitrate in biological fluids. Anal Biochem. 1982, 126, S.131-138,

108 Watanabe N, Kamei S, Ohikubo A et al.: Urinary protein as measured with a pyrogallol-molybdate complex, manually and in a Hitachi 726 automatic analyzer. Clin Chem. 1986, 32, S.1551-1554,

109 Watanabe G, Tomiyama H, Doba N: Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens. 2000, 18, S.229-234,

110 Maxwell AJ, Cooke JP: Cardiovascular effects of L-arginine. Curr Opin Nephrol Hypertens. 1998, 7, S.63-70,

11 1 Sigmon DH, Gonzales-Feldman E, Cavasin MA, Potter DL, Beierwal WH: Role of nitric oxide in the renal hemodynamic response to unilateral nephropathy. J Am Soc Nephrol. 2004, 15(6), S.1413-1420,

11 2 Six I, Van Belle E, Bordet R, Corseaux D, Callebert J, Dupuis B, Bauters C, Bertrand ME: L-Arginine and L-NAME have no effects on the reendotheliazation process after arterial balloon injury. Cardiovascular Research. 1999, 43, S.731-738,

113 Ashab I, Peer G, Blum M et al.: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int. 1995, 47, S.1515-1521,

114 Krumenacker JS, Hanafy KA, Murad F: Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull. 2004, 62 (6), S. 505-15,

115 Marletta, MA: Nitric oxide synthase structure and mechanism. J Biol Chem. 1993, 268, S. 12231- 12234,

116 Murad, F: Cellular signaling with nitric oxide and cyclic GMP. Braz J Med Biol Res. 1999, 32 (11), S. 1317-1327,

117 Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994, 269, S. 13725- 13728,

118 Malinski T, Taha Z: Nitric oxide release from a single cell measured in situ by a porphyrinic-based microsensor. Nature. 1992, 358 (6388), S. 676-678,

119 Sandau KB, Brune B: Molecular actions of nitric oxide in mesangial cells. Histol Histopathol. 2000, 15 (4), S. 1151-1158,

120 Murad F: The excitement and rewards of research with our discovery of some of the biological effects of nitric oxide. Circ Res. 2003, 92 (4), S. 339-341,

121 Radi R, Beckman JS, Bush KM, Freeman BA: Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J Biol Chem. 1991, 266 (7), S. 4244-4250,

122 Lowenstein CJ, Dinerman JL, Snyder SH: Nitric oxide: A physiologic messenger. Ann Intern Med. 1994; 120 (3), S. 227-237

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 4.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am: